|
|
News Breaks | | | | November 8, 2012 | | 05:19 EDT |  | CORT | Corcept Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray downgraded Corcept Therapeutics to Underweight citing the positive FDA panel vote for Novartis’s Signifor, a direct competitor to Corcept's Korlym. The firm lowered its price target for shares to $1.10 from $3. | |
|
News For CORT From The Last 14 Days Check below for free stories on CORT the last two weeks. |
|
|
| May 24, 2013 | | 17:22 EDT |  | CORT | Corcept Therapeutics enters services agreement with Centric Health
Corcept Therapeutics disclosed in a regulatory filing that on May 21, the company entered into a services agreement with Centric Health Resources to provide the exclusive specialty pharmacy and patient services program for the company's drug Korlym, starting early in Q3. Under the terms of the agreement, subject to certain exceptions, Centric will act as the exclusive specialty pharmacy distributor of the product in the United States for the term of the agreement. The initial term of the agreement is a period of three years from the initiation of services under the agreement. | |
|
|
|
|
|
|
